Epigenetic inactivation of secreted frizzled-related protein 2 in esophageal squamous cell carcinoma.

World Journal of Gastroenterology : WJG
Xiao-Wen HaoShu-tian Zhang

Abstract

To investigate the expression and methylation status of the secreted frizzled-related protein 2 (SFRP2) in esophageal squamous cell carcinoma (ESCC) and explore its role in ESCC carcinogenesis. Seven ESCC cell lines (KYSE 30, KYSE150, KYSE410, KYSE510, EC109, EC9706 and TE-1) and one immortalized human esophageal epithelial cell line (Het-1A), 20 ESCC tissue samples and 20 paired adjacent non-tumor esophageal epithelial tissues were analyzed in this study. Reverse-transcription polymerase chain reaction (RT-PCR) was employed to investigate the expression of SFRP2 in cell lines, primary ESCC tumor tissue, and paired adjacent normal tissue. Methylation status was evaluated by methylation-specific PCR and bisulfite sequencing. The correlation between expression and promoter methylation of the SFRP2 gene was confirmed with treatment of 5-aza-2'-deoxycytidine. To assess the potential role of SFRP2 in ESCC, we established stable SFRP2-transfected cells and examined them with regard to cell proliferation, colony formation, apoptosis and cell cycle in vivo and in vitro. SFRP2 mRNA was expressed in the immortalized normal esophageal epithelial cell line but not in seven ESCC cell lines. By methylation-specific PCR, complete methylation ...Continue Reading

References

Feb 1, 1990·American Journal of Obstetrics and Gynecology·G E PalomakiJ E Haddow
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·A RattnerJ Nathans
Apr 3, 2003·Nature Reviews. Cancer·Peter W Laird
May 31, 2003·Journal of Cell Science·Yoshiaki Kawano, Robert Kypta
Dec 6, 2003·The New England Journal of Medicine·Peter C Enzinger, Robert J Mayer
Apr 20, 2004·Lancet·Hannes M MüllerMartin Widschwendter
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eiji TamotoHiroyuki Katoh
Feb 17, 2005·Journal of the National Cancer Institute·Qinghua FengNancy B Kiviat
Feb 24, 2006·Nature Reviews. Cancer·Stephen B Baylin, Joyce E Ohm
Jan 19, 2008·World Journal of Gastroenterology : WJG·Dao-Rong Wang, Dong Tang
Feb 20, 2008·British Journal of Cancer·H SuzukiT Tokino
Mar 14, 2008·The New England Journal of Medicine·Manel Esteller
Apr 25, 2008·Nature Reviews. Cancer·Alexandra Klaus, Walter Birchmeier
Jul 2, 2008·Journal of Gastroenterology·Hideyasu TakagiYasuhisa Shinomura
Oct 22, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N RamírezJ García-Foncillas
May 27, 2010·Molecular Cancer Therapeutics·Soichiro YamamuraRajvir Dahiya
May 27, 2010·British Journal of Cancer·P WorkmanUNKNOWN Committee of the National Cancer Research Institute

❮ Previous
Next ❯

Citations

Sep 5, 2013·Frontiers of Medicine·Li Shang, Mingrong Wang
Jul 4, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yu LianYifeng Chen
Oct 4, 2019·Technology in Cancer Research & Treatment·Qian LiuYu-Qing Ma
Dec 23, 2020·Seminars in Cancer Biology·Vanessa Ortiz-BarahonaManel Esteller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.